AmyScan Healthcare aims to transform how amyloid-based neurodegenerative diseases are diagnosed, starting with Parkinson’s disease. Here, we are developing minimally invasive, cost-effective blood tests that detect disease-specific amyloid markers, enabling timely intervention and improved patient outcomes. At the heart of our innovation is a patented amplification technology, a process similar to PCR. This amplification platform enables the detection of ultra-low levels of circulating amyloid seeds in blood. These amyloid seeds are the key biomarkers of many neurodegenerative diseases, including Parkinson’s disease. Our approach will provide highly sensitive and specific results, even when biomarker levels are minimal, potentially empowering clinicians to make faster and more accurate decisions.

Built on more than a decade of research led by our founder, Prof. Dr. Samir Maji, a global expert in protein misfolding, aggregation, and amyloid biology. Prof. Maji has conducted research at leading institutions including Harvard Medical School, UCLA, the Salk Institute, and ETH Zurich. Currently a Professor at IIT Bombay and Professor-in-Charge at SCAN, he brings unparalleled expertise in the biology of Parkinson’s and Alzheimer’s to our translational mission